Association of Oxidative Stress with Disease Activity and Damage in Systemic Lupus Erythematosus: A Cross Sectional Study from a Tertiary Care Centre in Southern India
Overview
Affiliations
To study oxidative stress in systemic lupus erythematosus (SLE) by estimating serum oxidised LDL (OxLDL), 8-hydroxy-2'-deoxyguanosine (8-OHdG), malondialdehyde (MDA), and total anti-oxidant status and to correlate with SLE disease activity and disease damage. Eighty SLE patients satisfying the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) 2012 criteria and 80 healthy controls were studied. Exclusion criteria were infections, renal insufficiency, other connective tissue diseases, drug-induced lupus, smoking, alcohol consumption. Disease activity was measured by SLE disease activity index-2 K (SLEDAI), disease damage was quantified by SLICC-Damage Index (SDI). Sera was tested for OxLDL, 8-OHdG, and total antioxidant status (TAS) by double-antibody sandwich ELISA; MDA measured by . Oxidative stress markers were compared between group1- controls, group 2-mildly active SLE (SLEDAI ≤ 5), group 3- moderate to highly active SLE (SLEDAI ≥ 6). SLE patients had significantly higher MDA, 8-OHdG and lower TAS when compared to healthy controls, while OxLDL was similar in the three groups. MDA, 8-OHdG were significantly higher, TAS lower in group 3 compared to group 2. MDA had positive correlation with SLEDAI, TAS negatively correlated with SLEDAI. SLE with neuropsychiatric manifestations, vasculitis, anti-sdDNA antibodies had higher MDA, MDA/TAS ratio. SLE patients with thrombocytopenia, and vasculitis had higher OxLDL. Only OxLDL was significantly higher in those patients who have SDI > 1. SLE patients have increased oxidative stress measured by increases in MDA, 8-OHdG, and lower total antioxidant status that was associated with disease activity and some disease manifestations. However only OxLDL was associated with damage.
Intricating connections: the role of ferroptosis in systemic lupus erythematosus.
Zhao G, Li X, Zhang Y, Wang X, Deng L, Xu J Front Immunol. 2025; 16:1534926.
PMID: 39967676 PMC: 11832682. DOI: 10.3389/fimmu.2025.1534926.
Antioxidant and Anti-Apoptotic Neuroprotective Effects of Cinnamon in Imiquimod-Induced Lupus.
Maalouly G, Martin C, Baz Y, Saliba Y, Baramili A, Fares N Antioxidants (Basel). 2024; 13(7).
PMID: 39061948 PMC: 11274315. DOI: 10.3390/antiox13070880.
The Role of the Oxidative State and Innate Immunity Mediated by TLR7 and TLR9 in Lupus Nephritis.
Echavarria R, Cardona-Munoz E, Ortiz-Lazareno P, Andrade-Sierra J, Gomez-Hermosillo L, Casillas-Moreno J Int J Mol Sci. 2023; 24(20).
PMID: 37894915 PMC: 10607473. DOI: 10.3390/ijms242015234.
Ibrahim-Achi Z, Jorge-Perez P, Abreu-Gonzalez P, Lopez-Mejias R, Martin-Gonzalez C, Gonzalez-Gay M Antioxidants (Basel). 2023; 12(9).
PMID: 37759971 PMC: 10525833. DOI: 10.3390/antiox12091668.
Evaluation of NADPH Oxidase (NOX) Activity by nitro Blue Tetrazolium (NBT) Test in SLE Patients.
Baisya R, Katkam S, Ks S, Devarasetti P, Kutala V, Rajasekhar L Mediterr J Rheumatol. 2023; 34(2):163-171.
PMID: 37654639 PMC: 10466355. DOI: 10.31138/mjr.34.2.163.